Aarkstore - Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014

1
Resistant Pseudomonas Aeruginosa Infections -
Pipeline Review, H2 2014
Healthcare Market Research Reports
2
Summary

• Resistant Pseudomonas Aeruginosa Infections -
  Pipeline Review, H2 2014, provides an overview
  of the Resistant Pseudomonas Aeruginosa
  Infectionss therapeutic pipeline.This report
  provides comprehensive information on the
  therapeutic development for Resistant Pseudomonas
  Aeruginosa Infections, complete with comparative
  analysis at various stages, therapeutics
  assessment by drug target, mechanism of action
  (MoA), route of administration (RoA) and molecule
  type, along with latest updates, and featured
  news and press releases. It also reviews key
  players involved in the therapeutic development
  for Resistant Pseudomonas Aeruginosa Infections
  and special features on late-stage and
  discontinued projects.
• Global Markets Directs report features
  investigational drugs from across globe covering
  over 20 therapy areas and nearly 3,000
  indications. The report is built using data and
  information sourced from Global Markets Directs
  proprietary databases, Company/University
  websites, SEC filings, investor presentations and
  featured press releases from company/university
  sites and industry-specific third party sources,
  put together by Global Markets Directs team.
  Drug profiles/records featured in the report
  undergoes periodic updation following a stringent
  set of processes that ensures that all the
  profiles are updated with the latest set of
  information. 

3
Scope

• - The report provides a snapshot of the global
  therapeutic landscape of Resistant Pseudomonas
  Aeruginosa Infections- The report reviews key
  pipeline products under drug profile section
  which includes, product description, MoA and RD
  brief, licensing and collaboration details
  other developmental activities - The report
  reviews key players involved in the therapeutics
  development for Resistant Pseudomonas Aeruginosa
  Infections and enlists all their major and minor
  projects- The report summarizes all the dormant
  and discontinued pipeline projects - A review of
  the Resistant Pseudomonas Aeruginosa Infections
  products under development by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources- Pipeline products
  coverage based on various stages of development
  ranging from pre-registration till discovery and
  undisclosed stages- A detailed assessment of
  monotherapy and combination therapy pipeline
  projects- Coverage of the Resistant Pseudomonas
  Aeruginosa Infections pipeline on the basis of
  target, MoA, route of administration and molecule
  type- Latest news and deals relating related to
  pipeline products

4
Reasons to buy

• - Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies- Identify
  emerging players with potentially strong product
  portfolio and create effective counter-strategies
  to gain competitive advantage- Develop strategic
  initiatives by understanding the focus areas of
  leading companies- Identify and understand
  important and diverse types of therapeutics under
  development for Resistant Pseudomonas Aeruginosa
  Infections- Plan mergers and acquisitions
  effectively by identifying key players of the
  most promising pipeline- Devise corrective
  measures for pipeline projects by understanding
  Resistant Pseudomonas Aeruginosa Infections
  pipeline depth and focus of Indication
  therapeutics- Develop and design in-licensing
  and out-licensing strategies by identifying
  prospective partners with the most attractive
  projects to enhance and expand business potential
  and Scope- Modify the therapeutic portfolio by
  identifying discontinued projects and
  understanding the factors that drove them from
  pipeline

5
Table of Content

• List of Tables 5List of Figures 5Introduction
  6Global Markets Direct Report Coverage
  6Resistant Pseudomonas Aeruginosa Infections
  Overview 7Therapeutics Development 8Pipeline
  Products for Resistant Pseudomonas Aeruginosa
  Infections - Overview 8Pipeline Products for
  Resistant Pseudomonas Aeruginosa Infections -
  Comparative Analysis 9Resistant Pseudomonas
  Aeruginosa Infections - Therapeutics under
  Development by Companies 10Resistant Pseudomonas
  Aeruginosa Infections - Therapeutics under
  Investigation by Universities/Institutes
  11Resistant Pseudomonas Aeruginosa Infections -
  Pipeline Products Glance 12Clinical Stage
  Products 12Early Stage Products 13Resistant
  Pseudomonas Aeruginosa Infections - Products
  under Development by Companies 14

6
List of Tables

• Number of Products under Development for
  Resistant Pseudomonas Aeruginosa Infections, H2
  2014 8Number of Products under Development for
  Resistant Pseudomonas Aeruginosa Infections -
  Comparative Analysis, H2 2014 9Number of
  Products under Development by Companies, H2 2014
  10Number of Products under Investigation by
  Universities/Institutes, H2 2014 11Comparative
  Analysis by Clinical Stage Development, H2 2014
  12Comparative Analysis by Early Stage
  Development, H2 2014 13Products under
  Development by Companies, H2 2014 14Products
  under Investigation by Universities/Institutes,
  H2 2014 15Resistant Pseudomonas Aeruginosa
  Infections - Pipeline by AstraZeneca PLC, H2 2014
  16Resistant Pseudomonas Aeruginosa Infections -
  Pipeline by Biolytics Pharma, H2 2014
  17Resistant Pseudomonas Aeruginosa Infections -
  Pipeline by FOB Synthesis, Inc., H2 2014
  18Resistant Pseudomonas Aeruginosa Infections -
  Pipeline by LegoChem Biosciences, Inc, H2 2014 19

7
List of Figures

• Number of Products under Development for
  Resistant Pseudomonas Aeruginosa Infections, H2
  2014 8Number of Products under Development for
  Resistant Pseudomonas Aeruginosa Infections -
  Comparative Analysis, H2 2014 9Number of
  Products under Development by Companies, H2 2014
  10Comparative Analysis by Clinical Stage
  Development, H2 2014 12Comparative Analysis by
  Early Stage Products, H2 2014 13Assessment by
  Monotherapy Products, H2 2014 25Number of
  Products by Top 10 Targets, H2 2014 27Number of
  Products by Stage and Top 10 Targets, H2 2014
  27Number of Products by Top 10 Mechanism of
  Actions, H2 2014 29Number of Products by Stage
  and Top 10 Mechanism of Actions, H2 2014
  29Number of Products by Top 10 Routes of
  Administration, H2 2014 31Number of Products by
  Stage and Top 10 Routes of Administration, H2
  2014 31Number of Products by Top 10 Molecule
  Types, H2 2014 33

8
Browse Full Report

• Or Sample Request _at_
• http//www.aarkstore.com/healthcare/89708/resistan
  t-pseudomonas-aeruginosa-infections-pipeline-revie
  w-h2

9
Related Reports

• Healthcare IT (HIT) Market in the APAC Region
  2015-2019
• Complete 2015-16 Induced Pluripotent Stem Cell
  (iPSC) Industry Report
• Colposcopy Test, Market, Users Forecast - Asia
  Middle East Analysis
• Asia Intrauterine Device (IUD) Market, Users
  Forecast
• Global Nuclear Imaging Market 2015-2019
• Point of Care Diagnostic Testing World Markets
• European Non-Invasive Minimally Invasive
  Cardiac Output Monitoring Devices Market
• Europe Laboratory Information System Market

10
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
11
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953